Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery
Primary Purpose
Cataract
Status
Completed
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
Tobramycin 0.3% - Dexamethasone 0.1%
Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
Sponsored by
About this trial
This is an interventional treatment trial for Cataract focused on measuring Cataract, Phacoemulsification, Treatment duration
Eligibility Criteria
Inclusion Criteria:
- Phacoemulsification (due to cataract)
- Uneventful phacoemulsification surgery
Exclusion Criteria:
- Disruption of the anterior lens capsule
- Age-related macular degeneration
- Proliferative diabetic retinopathy
- Glaucoma
Sites / Locations
- Department of Ophthalmology, Veroia General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Tobramycin 0.3% - Dexamethasone 0.1%
Tobramycin-Dexamethasone plus Ketorolac tromethamine
Arm Description
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00992355
First Posted
October 8, 2009
Last Updated
October 8, 2009
Sponsor
Veroia General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00992355
Brief Title
Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery
Official Title
Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
April 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Veroia General Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This randomized controlled trial compares two regimens of topical therapy:
tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day
combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three times/day. The topical treatment is administered for 28 days after phacoemulsification.
Patients are independently assessed by two ophthalmologists. On day 28, patients are evaluated for
corneal edema
conjunctival redness
anterior chamber reaction. Moreover, the cases necessitating continuation of treatment are compared in the two groups on day 28 and 42.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract
Keywords
Cataract, Phacoemulsification, Treatment duration
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
97 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tobramycin 0.3% - Dexamethasone 0.1%
Arm Type
Active Comparator
Arm Title
Tobramycin-Dexamethasone plus Ketorolac tromethamine
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Tobramycin 0.3% - Dexamethasone 0.1%
Intervention Type
Drug
Intervention Name(s)
Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Phacoemulsification (due to cataract)
Uneventful phacoemulsification surgery
Exclusion Criteria:
Disruption of the anterior lens capsule
Age-related macular degeneration
Proliferative diabetic retinopathy
Glaucoma
Facility Information:
Facility Name
Department of Ophthalmology, Veroia General Hospital
City
Veroia
ZIP/Postal Code
59100
Country
Greece
12. IPD Sharing Statement
Learn more about this trial
Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery
We'll reach out to this number within 24 hrs